TP53 and colorectal carcinoma: In summary, through precise comparisons of different subclones of cancer cells in vivo from the same patients based on point mutations, CNVs, and transcriptomic characteristics all at single-cell resolutions, our data clearly offers mechanistic insights for the potential functional involvement of driver mutations (such as TP53, BRAF, and KRAS) in CRC patients in vivo.